Remove Cosmetics Remove Development Remove In-Vivo
article thumbnail

SkinVive by Juvéderm: The New Dermal Filler Coming to the US

XTalks

Allergan Aesthetics, an AbbVie company renowned for its development of leading aesthetics brands and products, recently announced the US Food and Drug Administration (FDA) approved their ground-breaking hyaluronic acid product, SkinVive by Juvéderm, for achieving remarkable skin smoothness. mL to sustain the desired effect.

Filler 92
article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog

While this hype may be warranted in some respects—a 60-year old legal provision has now been amended to acknowledge that the science of drug development is advancing—the change is mostly symbolic and is likely to take many years before we see it have a measurable impact. Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Is Confirmatory Evidence Having a Moment?

FDA Law Blog

We use the term “confirmatory evidence” as short-hand for one of the two ways explicitly defined in the Federal Food Drug & Cosmetic Act (“FD&C Act”) for demonstrating substantial evidence of effectiveness. More importantly, replication is but one means to substantiate the results of a clinical investigation or scientific study.

article thumbnail

Liposome: A Novel Drug Delivery System

Roots Analysis

Introduction to Liposome Liposome was initially identified and described as swollen phospholipid systems, called Banghasomes, by British hematologist Alec D. Bangham, in 1961 at the Babraham Institute, University of Cambridge. The various therapeutic applications of liposomes in drug delivery have been highlighted in the figure.